Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease.


Journal

Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362

Informations de publication

Date de publication:
2022
Historique:
pubmed: 12 10 2021
medline: 28 4 2022
entrez: 11 10 2021
Statut: ppublish

Résumé

Previous studies showed that lifestyle behaviors (cigarette smoking, alcohol, coffee) are inversely associated with Parkinson's disease (PD). The prodromal phase of PD raises the possibility that these associations may be explained by reverse causation. To examine associations of lifestyle behaviors with PD using two-sample Mendelian randomisation (MR) and the potential for survival and incidence-prevalence biases. We used summary statistics from publicly available studies to estimate the association of genetic polymorphisms with lifestyle behaviors, and from Courage-PD (7,369 cases, 7,018 controls; European ancestry) to estimate the association of these variants with PD. We used the inverse-variance weighted method to compute odds ratios (ORIVW) of PD and 95%confidence intervals (CI). Significance was determined using a Bonferroni-corrected significance threshold (p = 0.017). We found a significant inverse association between smoking initiation and PD (ORIVW per 1-SD increase in the prevalence of ever smoking = 0.74, 95%CI = 0.60-0.93, p = 0.009) without significant directional pleiotropy. Associations in participants ≤67 years old and cases with disease duration ≤7 years were of a similar size. No significant associations were observed for alcohol and coffee drinking. In reverse MR, genetic liability toward PD was not associated with smoking or coffee drinking but was positively associated with alcohol drinking. Our findings are in favor of an inverse association between smoking and PD that is not explained by reverse causation, confounding, and survival or incidence-prevalence biases. Genetic liability toward PD was positively associated with alcohol drinking. Conclusions on the association of alcohol and coffee drinking with PD are hampered by insufficient statistical power.

Sections du résumé

BACKGROUND
Previous studies showed that lifestyle behaviors (cigarette smoking, alcohol, coffee) are inversely associated with Parkinson's disease (PD). The prodromal phase of PD raises the possibility that these associations may be explained by reverse causation.
OBJECTIVE
To examine associations of lifestyle behaviors with PD using two-sample Mendelian randomisation (MR) and the potential for survival and incidence-prevalence biases.
METHODS
We used summary statistics from publicly available studies to estimate the association of genetic polymorphisms with lifestyle behaviors, and from Courage-PD (7,369 cases, 7,018 controls; European ancestry) to estimate the association of these variants with PD. We used the inverse-variance weighted method to compute odds ratios (ORIVW) of PD and 95%confidence intervals (CI). Significance was determined using a Bonferroni-corrected significance threshold (p = 0.017).
RESULTS
We found a significant inverse association between smoking initiation and PD (ORIVW per 1-SD increase in the prevalence of ever smoking = 0.74, 95%CI = 0.60-0.93, p = 0.009) without significant directional pleiotropy. Associations in participants ≤67 years old and cases with disease duration ≤7 years were of a similar size. No significant associations were observed for alcohol and coffee drinking. In reverse MR, genetic liability toward PD was not associated with smoking or coffee drinking but was positively associated with alcohol drinking.
CONCLUSION
Our findings are in favor of an inverse association between smoking and PD that is not explained by reverse causation, confounding, and survival or incidence-prevalence biases. Genetic liability toward PD was positively associated with alcohol drinking. Conclusions on the association of alcohol and coffee drinking with PD are hampered by insufficient statistical power.

Identifiants

pubmed: 34633332
pii: JPD212851
doi: 10.3233/JPD-212851
pmc: PMC9211765
mid: NIHMS1789361
doi:

Substances chimiques

Coffee 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

267-282

Subventions

Organisme : NIEHS NIH HHS
ID : R01 ES010758
Pays : United States
Organisme : NIA NIH HHS
ID : K24 AG000949
Pays : United States
Organisme : Intramural NIH HHS
ID : Z99 AG999999
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG008724
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 AG000949
Pays : United States
Organisme : Medical Research Council
Pays : United Kingdom

Références

Genet Epidemiol. 2016 May;40(4):304-14
pubmed: 27061298
Int J Epidemiol. 2019 Jun 1;48(3):912-925
pubmed: 30462234
Sci Rep. 2021 Jul 7;11(1):13980
pubmed: 34234189
Epidemiology. 2015 Mar;26(2):e15-6
pubmed: 25643110
Neurobiol Aging. 2017 Sep;57:247.e9-247.e13
pubmed: 28602509
JAMA Neurol. 2018 Jan 1;75(1):9-10
pubmed: 29131880
Stat Med. 2008 Apr 15;27(8):1133-63
pubmed: 17886233
Epidemiology. 2019 Nov;30(6):813-816
pubmed: 31373921
Wellcome Open Res. 2019 Nov 26;4:186
pubmed: 32760811
Int J Epidemiol. 2016 Dec 1;45(6):1961-1974
pubmed: 27616674
Nat Genet. 2019 Feb;51(2):237-244
pubmed: 30643251
Biochim Biophys Acta. 2009 Feb;1794(2):282-90
pubmed: 19013262
Neurology. 2019 Oct 8;93(15):e1412-e1424
pubmed: 31527283
Genet Epidemiol. 2013 Nov;37(7):658-65
pubmed: 24114802
Neurology. 2018 Feb 13;90(7):e583-e592
pubmed: 29352099
Neuroepidemiology. 1994;13(5):187-94
pubmed: 7969701
J Neurol. 2019 Aug;266(8):1821-1834
pubmed: 30155737
Soc Sci Med. 2018 Aug;210:70
pubmed: 29754782
Am J Epidemiol. 2013 Oct 1;178(7):1177-84
pubmed: 23863760
Eur J Neurol. 2018 Jan;25(1):120-127
pubmed: 28960663
PLoS Genet. 2016 Feb 11;12(2):e1005765
pubmed: 26866486
Eur J Epidemiol. 2017 May;32(5):377-389
pubmed: 28527048
Geriatr Gerontol Int. 2014 Apr;14(2):430-9
pubmed: 23879665
Psychol Med. 2020 Oct;50(14):2435-2443
pubmed: 31689377
Int J Epidemiol. 2017 Dec 1;46(6):1985-1998
pubmed: 29040600
JAMA Neurol. 2018 Apr 1;75(4):503-509
pubmed: 29459985
Lancet Neurol. 2019 Dec;18(12):1091-1102
pubmed: 31701892
Lancet Neurol. 2016 Nov;15(12):1257-1272
pubmed: 27751556
Int J Epidemiol. 2013 Oct;42(5):1497-501
pubmed: 24159078
Am J Epidemiol. 2002 Feb 1;155(3):265-72
pubmed: 11821252
Nat Genet. 2018 May;50(5):693-698
pubmed: 29686387
Hum Mol Genet. 2019 Jul 15;28(14):2449-2457
pubmed: 31046077
Mov Disord. 2019 Dec;34(12):1864-1872
pubmed: 31659794
Mov Disord. 1999 Nov;14(6):1011-3
pubmed: 10584678
Parkinsonism Relat Disord. 2016 Feb;23:1-9
pubmed: 26739246
Neurology. 2010 Mar 16;74(11):870-1
pubmed: 20220125
Arch Neurol. 2007 Jul;64(7):990-7
pubmed: 17620489
Ann Neurol. 2017 Nov;82(5):655-664
pubmed: 28981958
Mov Disord. 2012 Jul;27(8):947-57
pubmed: 22693036
Eur J Epidemiol. 2018 Oct;33(10):947-952
pubmed: 30039250
Ann Neurol. 2012 Dec;72(6):893-901
pubmed: 23071076
Rev Neurol (Paris). 2016 Aug - Sep;172(8-9):503-511
pubmed: 27503097
Neurology. 1997 Nov;49(5):1267-72
pubmed: 9371906
Bioinformatics. 2015 Nov 1;31(21):3555-7
pubmed: 26139635
BMJ. 2017 Dec 6;359:j5375
pubmed: 29212772
Neurology. 2001 Sep 25;57(6):1032-5
pubmed: 11571330
Bioinformatics. 2015 Apr 15;31(8):1334-6
pubmed: 25431330
Neurology. 2014 Oct 14;83(16):1396-402
pubmed: 25217056

Auteurs

Cloé Domenighetti (C)

Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, heredity, cancer and health", CESP, Villejuif, France.

Pierre-Emmanuel Sugier (PE)

Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, heredity, cancer and health", CESP, Villejuif, France.

Ashwin Ashok Kumar Sreelatha (AAK)

Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany.

Claudia Schulte (C)

Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Tubingen, Germany.

Sandeep Grover (S)

Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany.

Océane Mohamed (O)

Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, heredity, cancer and health", CESP, Villejuif, France.

Berta Portugal (B)

Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, heredity, cancer and health", CESP, Villejuif, France.

Patrick May (P)

Translational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg.

Dheeraj R Bobbili (DR)

Translational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg.
MeGeno S.A, Esch-sur-Alzette, Luxembourg.

Milena Radivojkov-Blagojevic (M)

Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany.

Peter Lichtner (P)

Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany.

Andrew B Singleton (AB)

Molecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD, USA.
Center For Alzheimer's and Related Dementias, NIA, NIH, Bethesda, MD, USA.

Dena G Hernandez (DG)

Molecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD, USA.

Connor Edsall (C)

Molecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD, USA.

George D Mellick (GD)

Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan, Queensland, Australia.

Alexander Zimprich (A)

Department of Neurology, Medical University of Vienna, Austria.

Walter Pirker (W)

Department of Neurology, Wilhelminenspital, Austria.

Ekaterina Rogaeva (E)

Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.

Anthony E Lang (AE)

Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada.
Division of Neurology, University of Toronto, Toronto, Ontario, Canada.
Krembil Brain Institute, Toronto, Ontario, Canada.

Sulev Koks (S)

Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, Australia.
Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia.

Pille Taba (P)

Department of Neurology and Neurosurgery, University of Tartu, Estonia.
Neurology Clinic, Tartu University Hospital, Tartu, Estonia.

Suzanne Lesage (S)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Department of Neurologie, Paris, France.

Alexis Brice (A)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Department of Neurologie, Paris, France.

Jean-Christophe Corvol (JC)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Department of Neurologie, Paris, France.
Assistance Publique Hôpitaux de Paris, Department of Neurology, CIC Neurosciences, Paris, France.

Marie-Christine Chartier-Harlin (MC)

Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - LilNCog- Centre de Recherche Lille Neurosciences & Cognition, Lille, France.

Eugénie Mutez (E)

Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - LilNCog- Centre de Recherche Lille Neurosciences & Cognition, Lille, France.

Kathrin Brockmann (K)

Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Tubingen, Germany.

Angela B Deutschländer (AB)

Department of Neurology, Ludwig Maximilians University of Munich, Germany.
Department of Neurology, Max Planck Institute of Psychiatry, Munich, Germany.
Department of Neurology and Department of Clinical Genomics, Mayo Clinic Florida, Jacksonville, FL, USA.

Georges M Hadjigeorgiou (GM)

Department of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece.
Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus.

Efthimos Dardiotis (E)

Department of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece.

Leonidas Stefanis (L)

1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Center of Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

Athina Maria Simitsi (AM)

1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Enza Maria Valente (EM)

Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation, Pavia, Italy.

Simona Petrucci (S)

UOC Medical Genetics and Advanced Cell Diagnostics, S. Andrea University Hospital, Rome, Italy.
Department of Clinical and Molecular Medicine, University of Rome, Rome, Italy.

Stefano Duga (S)

Department of Biomedical Sciences - Humanitas University, Milan, Italy.
Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.

Letizia Straniero (L)

Department of Biomedical Sciences - Humanitas University, Milan, Italy.

Anna Zecchinelli (A)

Parkinson Institute, Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italy.

Gianni Pezzoli (G)

Parkinson Institute, Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italy.

Laura Brighina (L)

Department of Neurology, San Gerardo Hospital, Monza, Italy.
Department of Medicine and Surgery and Milan Center for Neuroscience, University of Milano Bicocca, Milano, Italy.

Carlo Ferrarese (C)

Department of Neurology, San Gerardo Hospital, Monza, Italy.
Department of Medicine and Surgery and Milan Center for Neuroscience, University of Milano Bicocca, Milano, Italy.

Grazia Annesi (G)

Institute for Biomedical Research and Innovation, National Research Council, Cosenza, Italy.

Andrea Quattrone (A)

Institute of Neurology, Magna Graecia University, Catanzaro, Italy.

Monica Gagliardi (M)

Institute of Molecular Bioimaging and Physiology National Research Council, Catanzaro, Italy.

Hirotaka Matsuo (H)

Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Saitama, Japan.

Yusuke Kawamura (Y)

Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Saitama, Japan.

Nobutaka Hattori (N)

Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan.

Kenya Nishioka (K)

Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan.

Sun Ju Chung (SJ)

Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Yun Joong Kim (YJ)

Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea.

Pierre Kolber (P)

Neurology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.

Bart Pc van de Warrenburg (BP)

Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands.

Bastiaan R Bloem (BR)

Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands.

Jan Aasly (J)

Department of Neurology, St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway.

Mathias Toft (M)

Department of Neurology, Oslo University Hospital, Oslo, Norway.

Lasse Pihlstrøm (L)

Department of Neurology, Oslo University Hospital, Oslo, Norway.

Leonor Correia Guedes (LC)

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Department of Neurosciences and Mental Health, Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN), Lisbon, Portugal.

Joaquim J Ferreira (JJ)

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.

Soraya Bardien (S)

Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa.

Jonathan Carr (J)

Division of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa.

Eduardo Tolosa (E)

Parkinson's disease & Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona, Spain.

Mario Ezquerra (M)

Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Catalonia.

Pau Pastor (P)

Fundació per la Recerca Biomèdica i Social Mútua Terrassa, Terrassa, Barcelona, Spain.
Movement Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain.

Monica Diez-Fairen (M)

Fundació per la Recerca Biomèdica i Social Mútua Terrassa, Terrassa, Barcelona, Spain.
Movement Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain.

Karin Wirdefeldt (K)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Nancy L Pedersen (NL)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Caroline Ran (C)

Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Andrea C Belin (AC)

Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Andreas Puschmann (A)

Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden.

Clara Hellberg (C)

Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden.

Carl E Clarke (CE)

University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust, UK.

Karen E Morrison (KE)

Faculty of Medicine, Health and Life Sciences, Queens University, Belfast, UK.

Manuela Tan (M)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.

Dimitri Krainc (D)

Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Lena F Burbulla (LF)

Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Matt J Farrer (MJ)

Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.

Rejko Krüger (R)

Translational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg.
Neurology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.
Parkinson's Research Clinic, Centre Hospitalier de Luxembourg, Luxembourg.
Transversal Translational Medicine, Luxembourg Institute of Health (LIH), Strassen, Luxembourg.

Thomas Gasser (T)

Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Tubingen, Germany.

Manu Sharma (M)

Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany.
Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Germany.

Alexis Elbaz (A)

Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, heredity, cancer and health", CESP, Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH